These results indicate that the circulating clusterin modified at Asn374 by a biantennary sialyl N-glycan with homo Neu5Acα2,6Gal terminals is approximately 20% downregulated in RCC tumour patients as compared to healthy controls. Here, CLU is linked to neoplasm.